Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic diseases, has withdrawn registration for an $86.25 million IPO, due to “market conditions.” This is the second time in as many years that Aegerion has canceled a proposed IPO.
It had planned to trade on the Nasdaq, with Piper Jaffray and Thomas Weisel serving as co-lead underwriters. Aegerion has raised around $44 million in total VC funding, from firms like Index Ventures, Advent International, Alta Partners, Scheer & Co. and MVM Life Science Partners. www.aegerion.com
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.